Breaking News

Daiichi Sankyo Invests €1 Billion in Munich Site

Expansion will add capacity to make cardiovascular drugs and labs to develop and produce antibody drug conjugates (ADCs).

Daiichi Sankyo has announced plans to invest approximately $1.07 billion to expand a site near Munich, Germany, to boost its work on precision cancer drugs.
 
Reuters reports, the investment was announced as health minister Karl Lauterbach visited the center in Pfaffenhofen, north of Daiichi’s European headquarters in Munich.
 
The project will create 350 jobs by 2030 and will add capacity to make cardiovascular drugs and labs to develop and produce antibody drug conjugates (ADCs).
 
This news comes months after Depixus entered a collaboration with Daiichi Sankyo to use their novel MAGNA technology to accelerate Daiichi’s RNA-targeted drug discovery program.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters